Chronic treatment with rivastigmine in patients with Alzheimer's disease: A study on primary motor cortex excitability tested by 5Hz-repetitive transcranial magnetic stimulation

Clinical Neurophysiology

Volumn 123, Issue 5, 2012, Pages 902-909

  Trebbastoni, A ^a   Gilio, F ^b   D'Antonio, F ^a   Cambieri, C ^a   Ceccanti, M ^a   de Lena, C ^a   Inghilleri, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b S Pertini   (Italy)

Author keywords

Alzheimer's disease (AD); Cholinesterase inhibitor; Repetitive transcranial magnetic stimulation (rTMS); Synaptic plasticity

Indexed keywords

RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; AMPLITUDE MODULATION; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; EVOKED MUSCLE RESPONSE; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; SCORING SYSTEM; STIMULUS RESPONSE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; FUNCTIONAL LATERALITY; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MOTOR CORTEX; MUSCLE, SKELETAL; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; REACTION TIME; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84858751070     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2011.09.010     Document Type: Article

References (109)

1. Alagona G., Bella R., Ferri R., Carnemolla A., Pappalardo A., Costanzo E., et al. Transcranial magnetic stimulation in Alzheimer disease: motor cortex excitability and cognitive severity. Neurosci Lett 2001, 314:57-60.
2. Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988, 50:1914-1923.
3. Ballmaier M., Casamenti F., Scali C., Mazzoncini R., Zoli M., Pepeu G., et al. Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience 2002, 114:91-98.
4. Banerjee C, Nyengaard JR, Wevers A, de Vos RA, Jansen Steur EN, Lindstrom J et al. Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease - a stereological approach. Neurobiol Dis 2000;7:666-72. Erratum in: Neurobiol Dis 2001;8:358.
5. Battaglia F., Wang H.Y., Ghilardi M.F., Gashi E., Quartarone A., Friedman E., et al. Cortical plasticity in Alzheimer's disease in humans and rodents. Biol Psychiatry 2007, 62:1405-1412.
6. Bear M.F., Kirkwood A. Neocortical long-term potentiation. Curr Opin Neurobiol 1993, 3:197-202.
7. Berardelli A., Inghilleri M., Rothwell J.C., Romeo S., Currà A., Gilio F., et al. Facilitation of muscle evoked responses after repetitive cortical stimulation in man. Exp Brain Res 1998, 122:79-84.
8. Blitzer R.D., Gil O., Landau E.M. Cholinergic stimulation enhances long-term potentiation in the CA1 region of rat hippocampus. Neurosci Lett 1990, 119:207-210.
9. Blokland A. Acetylcholine: a neurotransmitter for learning and memory?. Brain Res Brain Res Rev 1995, 21:285-300.
10. Boada-Rovira M., Brodaty H., Cras P., Baloyannis S., Emre M., Zhang R., et al. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging 2004, 21:43-53.
11. Bröcher S., Artola A., Singer W. Agonists of cholinergic and noradrenergic receptors facilitate synergistically the induction of long-term potentiation in slices of rat visual cortex. Brain Res 1992, 573:27-36.
12. Burghaus L., Schütz U., Krempel U., de Vos R.A., Jansen Steur E.N., Wevers A., et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 2000, 76:385-388.
13. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999, 2:271-276.
14. Chen Q.S., Kagan B.L., Hirakura Y., Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 2000, 60:65-72.
15. Crews L., Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 2010, 19:R12-R20.
16. Crews L., Adame A., Patrick C., Delaney A., Pham E., Rockenstein E., et al. Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis. J Neurosci 2010, 30:12252-12262.
17. Cullen W.K., Suh Y.H., Anwyl R., Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 1997, 8:3213-3217.
18. Cummings J., Lefèvre G., Small G., Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007, 69(Suppl. 1):S10-S13.
19. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403.
20. de Carvalho M., de Mendonça A., Miranda P.C., Garcia C., Luís M.L. Magnetic stimulation in Alzheimer's disease. J Neurol 1997, 244:304-307.
21. Di Lazzaro V., Oliviero A., Tonali P.A., Marra C., Daniele A., Profice P., et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 2002, 59:392-397.
22. Di Lazzaro V., Oliviero A., Tonali P.A., Mazzone P., Insola A., Pilato F., et al. Direct demonstration of reduction of the output of the human motor cortex induced by a fatiguing muscle contraction. Exp Brain Res 2003, 149:535-538.
23. Di Lazzaro V., Oliviero A., Pilato F., Saturno E., Dileone M., Tonali P.A. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease: evidence of impaired glutamatergic neurotransmission?. Ann Neurol 2003, 53(824):824-825.
24. Di Lazzaro V., Oliviero A., Pilato F., Saturno E., Dileone M., Marra C., et al. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:555-559.
25. Feig S., Lipton P. Pairing the cholinergic agonist carbachol with patterned Schaffer collateral stimulation initiates protein synthesis in hippocampal CA1 pyramidal cell dendrites via a muscarinic, NMDA-dependent mechanism. J Neurosci 1993, 13:1010-1021.
26. Fernández de Sevilla D., Buño W. The muscarinic long-term enhancement of NMDA and AMPA receptor-mediated transmission at Schaffer collateral synapses develop through different intracellular mechanisms. J Neurosci 2010, 30:11032-11042.
27. Ferreri F., Pauri F., Pasqualetti P., Fini R., Dal Forno G., Rossini P.M. Motor cortex excitability in Alzheimer's disease: a transcranial magnetic stimulation study. Ann Neurol 2003, 53:102-108.
28. Ferreri F., Pasqualetti P., Määttä S., Ponzo D., Guerra A., Bressi F., et al. Motor cortex excitability in Alzheimer's disease: a transcranial magnetic stimulation follow-up study. Neurosci Lett 2011, 492:94-98.
29. Francis P.T., Sims N.R., Procter A.W., Bowen D.M. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 1993, 60:1589-1604.
30. Freir D.B., Holscher C., Herron C.E. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol 2001, 85:708-713.
31. Freund T.F. Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci 2003, 26:489-495.
32. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
33. Fujii S., Ji Z., Morita N., Sumikawa K. Acute and chronic nicotine exposure differentially facilitate the induction of LTP. Brain Res 1999, 846:137-143.
34. Garzon D.J., Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 2007, 27:2628-2635.
35. Gilio F., Iacovelli E., Conte A., Frasca V., Gabriele M., Giacomelli E., et al. Asymmetric responses to repetitive transcranial magnetic stimulation (rTMS) over the left and right primary motor cortex in a patient with lateralized progressive limb-kinetic apraxia. Neurosci Lett 2008, 437:125-129.
36. Grundman M., Corey-Bloom J., Thal L.J. Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. J Neural Transm Suppl 1998, 53:255-275.
37. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000, 74:237-243.
38. Gureviciene I., Ikonen S., Gurevicius K., Sarkaki A., van Groen T., Pussinen R., et al. Normal induction but accelerated decay of LTP in APP+PS1 transgenic mice. Neurobiol Dis 2004, 15:188-195.
39. Hasselmo M.E., Barkai E. Cholinergic modulation of activity-dependent synaptic plasticity in the piriform cortex and associative memory function in a network biophysical simulation. J Neurosci 1995, 15:6592-6604.
40. Herry C., Garcia R. Prefrontal cortex long-term potentiation, but not long-term depression, is associated with the maintenance of extinction of learned fear in mice. J Neurosci 2002, 22:577-583.
41. Hess G., Donoghue J.P. Long-term potentiation and long-term depression of horizontal connections in rat motor cortex. Acta Neurobiol Exp (Wars) 1996, 56:397-405.
42. Howell O., Atack J.R., Dewar D., McKernan R.M., Sur C. Density and pharmacology of alpha5 subunit-containing GABA(A) receptors are preserved in hippocampus of Alzheimer's disease patients. Neuroscience 2000, 98:669-675.
43. Hynd M.R., Scott H.L., Dodd P.R. Quantitation of alternatively spliced NMDA receptor NR1 isoform mRNA transcripts in human brain by competitive RT-PCR. Brain Res Brain Res Protoc 2003, 11:52-66.
44. Ilić T.V., Meintzschel F., Cleff U., Ruge D., Kessler K.R., Ziemann U. Short-interval paired-pulse inhibition and facilitation of human motor cortex: the dimension of stimulus intensity. J Physiol 2002, 545:153-167.
45. Inghilleri M., Berardelli A., Cruccu G., Manfredi M. Silent period evoked by transcranial stimulation of the human cortex and cervicomedullary junction. J Physiol 1993, 466:521-534.
46. Inghilleri M., Conte A., Frasca V., Curra' A., Gilio F., Manfredi M., et al. Antiepileptic drugs and cortical excitability: a study with repetitive transcranial stimulation. Exp Brain Res 2004, 154:488-493.
47. Inghilleri M., Conte A., Frasca V., Gilio F., Lorenzano C., Berardelli A. Synaptic potentiation induced by rTMS: effect of lidocaine infusion. Exp Brain Res 2005, 163:114-117.
48. Inghilleri M., Conte A., Frasca V., Scaldaferri N., Gilio F., Santini M., et al. Altered response to rTMS in patients with Alzheimer's disease. Clin Neurophysiol 2006, 117:103-109.
49. Ji D., Lape R., Dani J.A. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 2001, 31:131-141.
50. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., et al. APP processing and synaptic function. Neuron 2003, 37:925-937.
51. Kim J.H., Anwyl R., Suh Y.H., Djamgoz M.B., Rowan M.J. Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci 2001, 21:1327-1333.
52. Klein W.L., Krafft G.A., Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci 2001, 24:219-224.
53. Kobayashi M., Pascual-Leone A. Transcranial magnetic stimulation in neurology. Lancet Neurol 2003, 2:145-156.
54. Korchounov A., Ilic T.V., Schwinge T., Ziemann U. Modification of motor cortical excitability by an acetylcholinesterase inhibitor. Exp Brain Res 2005, 164:399-405.
55. Kozhemyakin M., Rajasekaran K., Kapur J. Central cholinesterase inhibition enhances glutamatergic synaptic transmission. J Neurophysiol 2010, 103:1748-1757.
56. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998, 95:6448-6453.
57. Lang N., Nitsche M.A., Paulus W., Rothwell J.C., Lemon R.N. Effects of transcranial direct current stimulation over the human motor cortex on corticospinal and transcallosal excitability. Exp Brain Res 2004, 156:439-443.
58. Langguth B., Bauer E., Feix S., Landgrebe M., Binder H., Sand P., et al. Modulation of human motor cortex excitability by the cholinesterase inhibitor rivastigmine. Neurosci Lett 2007, 415:40-44.
59. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.
60. Liepert J., Schardt S., Weiller C. Orally administered atropine enhances motor cortex excitability: a transcranial magnetic stimulation study in human subjects. Neurosci Lett 2001, 300:149-152.
61. Liepert J., Bar K.J., Meske U., Weiller C. Motor cortex disinhibition in Alzheimer's disease. Clin Neurophysiol 2001, 112:1436-1441.
62. Mann E.O., Greenfield S.A. Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro. J Physiol 2003, 551:539-550.
63. Markram H., Segal M. Long-lasting facilitation of excitatory postsynaptic potentials in the rat hippocampus by acetylcholine. J Physiol 1990, 427:381-393.
64. Markram H., Segal M. Acetylcholine potentiates responses to N-methyl-d-aspartate in the rat hippocampus. Neurosci Lett 1990, 113:62-65.
65. Markram H., Segal M. The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA. J Physiol 1992, 447:513-533.
66. Marrosu F., Portas C., Mascia M.S., Casu M.A., Fà M., Giagheddu M., et al. Microdialysis measurement of cortical and hippocampal acetylcholine release during sleep-wake cycle in freely moving cats. Brain Res 1995, 671:329-332.
67. Martin-Ruiz C.M., Court J.A., Molnar E., Lee M., Gotti C., Mamalaki A., et al. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999, 73:1635-1640.
68. Mash D.C., Flynn D.D., Potter L.T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985, 228:1115-1117.
69. McGowan E., Eriksen J., Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006, 22:281-289.
70. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
71. Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Prog Brain Res 2004, 145:67-78.
72. Middei S., Roberto A., Berretta N., Panico M.B., Lista S., Bernardi G., et al. Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. Learn Mem 2010, 17:236-240.
73. Mintzer J.E., Kershaw P. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry 2003, 18:292-297.
74. Nitsche M.A., Roth A., Kuo M.F., Fischer A.K., Liebetanz D., Lang N., et al. Timing-dependent modulation of associative plasticity by general network excitability in the human motor cortex. J Neurosci 2007, 27:3807-3812.
75. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
76. Pennisi G., Alagona G., Ferri R., Greco S., Santonocito D., Pappalardo A., et al. Motor cortex excitability in Alzheimer disease: one year follow-up study. Neurosci Lett 2002, 329:293-296.
77. Perry E.K., Tomlinson B.E., Blessed G., Bergmann K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978, 2:1457-1459.
78. Quadros A., Patel N., Crescentini R., Crawford F., Paris D., Mullan M. Increased TNFalpha production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice. Neurosci Lett 2003, 353:66-68.
79. Radcliffe K.A., Dani J.A. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 1998, 18:7075-7083.
80. Raskind M.A., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000, 54:2261-2268.
81. Ridding M.C., Rothwell J.C. Stimulus/response curves as a method of measuring motor cortical excitability in man. Electroencephalogr Clin Neurophysiol 1997, 105:340-344.
82. Rothwell J.C., Thompson P.D., Day B.L., Marsden C.D. Stimulation of the human motor cortex through the scalp. Exp Physiol 1991, 76:159-200.
83. Rothwell J., Burke D., Hicks R., Stephen J., Woodforth I., Crawford M. Transcranial electrical stimulation of the motor cortex in man: further evidence for the site of activation. J Physiol 1994, 481:243-250.
84. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001, 3:75-80.
85. Selkoe D.J., Podlisny M.B. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002, 3:67-99.
86. Shemer I., Holmgren C., Min R., Fülöp L., Zilberter M., Sousa K.M., et al. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur J Neurosci 2006, 23:2035-2047.
87. Small D.H. Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression?. Trends Mol Med 2008, 14:103-108.
88. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8:1051-1058.
89. Teaktong T., Graham A.J., Court J.A., Perry R.H., Jaros E., Johnson M., et al. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology. J Neurol Sci 2004, 225:39-49.
90. Teaktong T., Graham A., Court J., Perry R., Jaros E., Johnson M., et al. Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 2003, 41:207-211.
91. Thorns V., Mallory M., Hansen L., Masliah E. Alterations in glutamate receptor 2/3 subunits and amyloid precursor protein expression during the course of Alzheimer's disease and Lewy body variant. Acta Neuropathol 1997, 94:539-548.
92. Tong L., Balazs R., Thornton P.L., Cotman C.W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 2004, 24:6799-6809.
93. Trinchese F., Liu S., Battaglia F., Walter S., Mathews P.M., Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004, 55:801-814.
94. Turrigiano G.G. Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Trends Neurosci 1999, 22:221-227.
95. Turrigiano G.G., Nelson S.B. Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci 2004, 5:97-107.
96. van Groen T., Kiliaan A.J., Kadish I. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 2006, 23:653-662.
97. Venkitaramani D.V., Chin J., Netzer W.J., Gouras G.K., Lesne S., Malinow R., et al. Beta-amyloid modulation of synaptic transmission and plasticity. J Neurosci 2007, 27:11832-11837.
98. Walsh D.M., Selkoe D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004, 11:213-228.
99. Wang H., Wang X., Scheich H. LTD and LTP induced by transcranial magnetic stimulation in auditory cortex. Neuroreport 1996, 7:521-525.
100. Watt A.J., van Rossum M.C., MacLeod K.M., Nelson S.B., Turrigiano G.G. Activity coregulates quantal AMPA and NMDA currents at neocortical synapses. Neuron 2000, 26:659-670.
101. Watt A.J., Sjöström P.J., Häusser M., Nelson S.B., Turrigiano G.G. A proportional but slower NMDA potentiation follows AMPA potentiation in LTP. Nat Neurosci 2004, 7:518-524.
102. Werhahn K.J., Kunesch E., Noachtar S., Benecke R., Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 1999, 517:591-597.
103. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 2151237-2151239.
104. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001, 57:489-495.
105. Winblad B., Cummings J., Andreasen N., Grossberg G., Onofrj M., Sadowsky C., et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007, 22:456-467.
106. Winblad B., Machado J.C. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008, 5:1377-1386.
107. Ye L., Qiao J.T. Suppressive action produced by beta-amyloid peptide fragment 31-35 on long-term potentiation in rat hippocampus is N-methyl-d-aspartate receptor-independent: it is offset by (-)huperzine A. Neurosci Lett 1999, 275:187-190.
108. Yu W.F., Guan Z.Z., Bogdanovic N., Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 2005, 192:215-225.
109. Ziemann U., Lönnecker S., Steinhoff B.J., Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996, 40:367-378.